LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Elenco Azioni・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

51.48 -1.45

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

51.07

Massimo

51.6

Metriche Chiave
By Trading Economics
Entrata	6.6M -39M
Vendite	19M 212M
P/E Media del settore	48.435 49.8
EPS	0.882
Margine di Profitto	-18.221
Dipendenti	778
EBITDA	127M 90M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+22.59% upside

Dividendi
By Dow Jones
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-106M 2.8B
Apertura precedente	52.93
Chiusura precedente	51.48

Notizie sul Sentiment di mercato

By Acuity

50%

159 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

31.35 / 32.36 Supporto e resistenza

Supernus Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 mag 2026, 06:05 UTC

Utili

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 mag 2026, 23:55 UTC

Utili

Review & Preview: Still Going Strong -- Barrons.com

8 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 mag 2026, 20:49 UTC

Utili

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mag 2026, 20:25 UTC

Utili

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mag 2026, 19:43 UTC

Utili

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mag 2026, 19:43 UTC

Utili

Cencosud 1Q Net $115M

8 mag 2026, 19:20 UTC

Discorsi di Mercato

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mag 2026, 19:18 UTC

Utili

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mag 2026, 19:16 UTC

Utili

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mag 2026, 19:08 UTC

Utili

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mag 2026, 19:05 UTC

Utili

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mag 2026, 19:02 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mag 2026, 18:51 UTC

Utili

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mag 2026, 18:49 UTC

Utili

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mag 2026, 18:41 UTC

Utili

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mag 2026, 17:38 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mag 2026, 17:14 UTC

Utili

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mag 2026, 17:04 UTC

Discorsi di Mercato

Zcash Caps Off Parabolic Week -- Market Talk

8 mag 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

8 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

8 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 mag 2026, 15:39 UTC

Discorsi di Mercato

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 mag 2026, 15:39 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 mag 2026, 15:39 UTC

Discorsi di Mercato

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 mag 2026, 15:36 UTC

Discorsi di Mercato

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 mag 2026, 15:20 UTC

Discorsi di Mercato

'Altcoin Season' Indicator on the Rise -- Market Talk

8 mag 2026, 15:20 UTC

Discorsi di Mercato

Utili

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 mag 2026, 15:05 UTC

Discorsi di Mercato

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 mag 2026, 14:42 UTC

Discorsi di Mercato

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

Confronto tra pari

Modifica del prezzo

Supernus Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

22.59% in crescita

Previsioni per 12 mesi

Media 63.17 USD 22.59%

Alto 66 USD

Basso 55 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Supernus Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Supernus Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

31.35 / 32.36Supporto e resistenza

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

159 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.